the aid library

LIST OPTIONS

Filter

6941

Sort by:

Direction:

Download (77)

View PDF (893)

Investing in drug-resistant tuberculosis household contact management and preventive treatment

Hussain.H.; Malik, A. A. The Lancet (2022) CC

Preventing tuberculosis infection from progressing to tuberculosis disease is a crucial component of the goal to eliminate tuberculosis. When deciding on the use of tuberculosis preventive therapy among household contacts, policy makers regularly ask questions, such as whether tuberculosis preventiv... more

Download (352)

View PDF (453)

Methods to estimate number of child household contacts less than 5 years old eligible for latent tuberculosis treatment

World Health Organization (2017) C_WHO

October 2017

Download (118)

View PDF (635)

National Guidelines on Nutrition Care, Support, and Treatment (NCST) for Adolescent and Adults. Second edition 2017

Ministry of Health Malawi (2017) CC

National Guidelines on Nutrition, Care, Support, and Treatment (NCST) for Adolescents and Adults These guidelines are intended to: • Establish a consistent set of nutrition interventions and recommendations aimed at managing and preventing undernutrition and overnutrition in adolescents and ad... more

Download (158)

View PDF (162)

A Review of Community Health Worker (CHW) knowledge, attitudes and practices relating to the sexual health of MSM, including existing training materials and manuals in Europe & neighbouring countries

C. Folch; P. Fernández-Dávila; J. Palacio-Vieira; et al. European Commission; Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT); European AIDS Treatment Group (2020) C2

Accessed: 07.03.2020 A Review of Community Health Worker (CHW) knowledge, attitudes and practices relating to the sexual health of MSM, including existing training materials and manuals in Europe and neighbouring countries (D5.1) Contract 2015 71 01 A behavioural survey for HIV/AIDS and assoc... more

Download (300)

View PDF (484)

Best practices in child and adolescent tuberculosis care
recommended

World Health Organization WHO (2018) C_WHO

Outstanding child and adolescent TB priorities include the need to: find the missing children with active TB and link them to TB care; prevent TB in children who are in contact with infectious TB cases (through implementation of active contact investigation and provision of preventive treatment); an... more

Download (29)

View PDF (36)

What is Addicition?

UCLA Brain Research Institute (2021) CC

The pamphlet "What is Addiction" explains addiction as a chronic, relapsing brain disease characterized by compulsive drug seeking and use, despite harmful consequences. It highlights the dangers of different drug categories, including sedatives, stimulants, and hallucinogens, and their potential he... more

Download (95)

View PDF (139)

occupied Palestinian territory COVID-19 Response Plan (27 March 2020)

UN Office for the Coordination of Humanitarian Affairs (OCHA) (2020) C_WHO

The primary focus of the plan continues to be prevention, preparedness and treatment of the the Novel Coronavirus (COVID-19) outbreak. Central to the plan are the following overall objectives: To prevent further transmission of COVID-19 in the oPt; To provide adequate care for patients aff... more

Download (93)

View PDF (346)

Scabies Continuing Education Activity

Gilson, R.; Crane, J. National Library of Medicine (2022) CC

Scabies is a contagious skin condition caused by the mite Sarcoptes scabiei which burrows into the skin and causes severe itching. Scabies is transmitted by direct skin-to-skin contact or indirectly by contact with contaminated material (fomites). This condition is often challenging to diagnose as m... more

Download (76)

View PDF (60)

Implications of the Marburg virus disease outbreak in Rwanda for the EU/EEA, 2024

European Centre for Disease Prevention and Control (ecdc) (2024) C_CDC

This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and, although uncommon, it has the potential to cause epidemics with significant case fatality. ... more

Download (85)

View PDF (341)

Integrated control of Chagas disease for its elimination as public health problem - A Review

Sosa-Estani, S.; Segura, E.L. Memórias do Instituto Oswaldo Cruz (2015) C2

Chagas disease or American trypanosomiasis is, together with geohelminths, the neglected disease that causes more loss of years of healthy life due to disability in Latin America. Chagas disease, as determined by the factors and determinants, shows that different contexts require different actions, ... more

Download (151)

View PDF (189)

Covid-19 Test to Treat Guidelines
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

n response to the outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) has been supporting African Union Member States in responding to the COVID-19 pandemic through a variety of interventions such as non-pharmaceutical interventions, quarantine, testing, isolation, contact t... more

Download (420)

View PDF (2628)

Community Ebola Toolkit

Community Health Global Network (2014)

The CHGN Ebola toolkit is a collection of resources that we hope will be of use to many of the organisations, agencies and individuals working to address the Ebola outbreak in English-speaking West Africa, particularly those engaged at the community-level. The focus of the toolkit is on community... more

Download (283)

View PDF (378)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (293)

View PDF (474)

Leprosy/Hansen disease: Contact tracing and post-exposure prophylaxis
recommended

World Health Organization WHO (2020) C_WHO

This document provides guidance on how to implement contact screening and chemoprophylaxis with single-dose rifampicin. The contents are logically ordered: counselling and obtaining consent, identification and listing of index case, listing of contacts, tracing of contacts, screening of contacts, ad... more

Download (131)

View PDF (1884)

What is Leishmaniasis?

Cafasso, J. Healthline (2018) CC

Leishmaniasis is a parasitic disease caused by the Leishmania parasite. This parasite typically lives in infected sand flies. You can contract leishmaniasis from a bite of an infected sand fly. The sand flies that carry the parasite typically reside in tropical and subtropical environments. Fatal... more

Download (166)

View PDF (188)

Risk communication and community engagement (RCCE) for monkeypox outbreaks: Interim guidance, 24 June 2022

World Health Organization WHO (2022) C_WHO

The Interim Guidance for Risk Communication and Community Engagement (RCCE) outlines recommendations, considerations and methods to raise awareness, manage risk perception, maintain trust and proactively support people at risk to make informed decisions to protect themselves and others from monkeypo... more

Download (1266)

View PDF (1563)

Algorithms for Managing Common STI Syndromes (Kenya)

Ministry of Health, Republic of Kenya (2017) C2

Accessed online January 2018

Download (203)

View PDF (185)

Childhood Tuberculosis: Diagnosis, Treatment and Prevention of TB in HIV-infected Children

C. DC Christie-Samuels World Health Organization (2019) C_WHO

Accessed: 21.10.2019

Download (558)

View PDF (839)

Safe Handling, Treatment, Transport and Disposal of Ebola-Contaminated Waste

OSHA Occupational Safety and Health Administration (2014)

Download (186)

View PDF (230)

Shorter treatment for children with minimal TB

SHINE Medical Research Council Clinical Trials Unit (MRC CTU) at UCL (2022) CC

The results of the SHINE trial have been published in the NEJM today. SHINE looked at whether treatment for children with minimal TB could be reduced from 6 months to 4 months. It found that the four month treatment was as good as the standard six months treatment for children with minimal TB

Best practices in child and adolescent tuberculosis care recommended

Covid-19 Test to Treat Guidelines recommended

Leprosy/Hansen disease: Contact tracing and post-exposure prophylaxis recommended

Best practices in child and adolescent tuberculosis care
recommended

Covid-19 Test to Treat Guidelines
recommended

Leprosy/Hansen disease: Contact tracing and post-exposure prophylaxis
recommended